Regional cardiac tissue treatment

• US 20100274173A1
• Filed: 04/14/2010
• Published: 10/28/2010
• Est. Priority Date: 02/26/2004
• Status: Active Grant

• Current Assignee: Osprey Medical, Inc.
• Original Assignee: Osprey Medical, Inc.
• Inventors: Byrne, Melissa Jane, Bilney, Adam Lucas, Kaye, David Martin, Shapland, James Edward, Doan, Tuan Minh
• Granted Patent: US 8,292,871 B2
• Time in Patent Office: Days
• US Class Current: 604/6.140
• CPC Class Codes: A61B 17/22 Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for dilators A61M29/00
• CPC Class Codes: A61B 2017/22082 after introduction of a substance
• CPC Class Codes: A61M 1/3653 Interfaces between patient blood circulation and extra-corporal blood circuit
• CPC Class Codes: A61M 1/3659 Cannulae pertaining to extracorporeal circulation
• CPC Class Codes: A61M 1/3667 with assisted venous return
• CPC Class Codes: A61M 2025/0031 characterized by lumina for withdrawing or delivering, i.e. used for extracorporeal circuit treatment
• CPC Class Codes: A61M 2027/004 with at least a part of the circuit outside the body
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00
• CPC Class Codes: A61M 25/104 used for angioplasty

Abstract

A method for treating an occlusion in a coronary artery of a patient includes percutaneously advancing an occlusion treatment tool (such as an angioplasty balloon or stent delivery device) through the vasculature of the patient and into a coronary artery to a site of the occlusion. Following the treatment of the occlusion, a therapeutic agent is admitted into the first coronary artery. The therapeutic agent is selected to treat microvasculature obstructions at a target cardiac tissue site distal to the site of the occlusion.

Claims

1. (canceled)

2. A method of treating a region of cardiac tissue, comprising the steps of:

a) perfusing the region of cardiac tissue, including administering a therapeutic agent to the region, the therapeutic agent being selected to treat microvascular obstructions; and

b) systemically isolating the administered therapeutic agent by withdrawing the agent prior to systemic circulation.

3. The method of claim 2, wherein the step of systemically isolating the administered therapeutic agent includes withdrawing the therapeutic agent at a location distal to the region.

4. The method of claim 2, wherein the region is distal to a cardiac occlusion location.

5. The method of claim 4, further including treating an occlusion at the cardiac occlusion location prior to perfusing the region.

6. The method of claim 5, further including advancing an occlusion treatment tool through a patient'"'"'s vasculature and into a coronary artery toward the cardiac occlusion location.

7. The method of claim 2, further including placing a perfusion catheter into a patient'"'"'s coronary artery and placing a collection catheter into the patient'"'"'s coronary vein.

8. The method of claim 2, wherein the step of systemically isolating includes withdrawing the therapeutic agent and an amount of blood.

9. The method of claim 8, further including admitting the withdrawn blood back into the patient'"'"'s vasculature.

10. The method of claim 9, further including oxygenating the withdrawn blood prior to admitting the withdrawn blood back into the patient'"'"'s vasculature.

11. The method of claim 8, further including discarding the withdrawn blood.

12. The method of claim 8, further including diverting a portion of the withdrawn blood, oxygenating the diverted portion of withdrawn blood, and admitting the diverted, oxygenated, withdrawn blood back into the patient'"'"'s vasculature.

13. The method of claim 2, furthering including assessing the region for microvascular obstructions.

14. The method of claim 13, wherein the step of assessing includes obtaining feedback from a flow rate measurement tool placed within a patient'"'"'s coronary artery.

15. The method of claim 13, wherein the step of assessing includes obtaining feedback from a pressure sensor placed within a patient'"'"'s coronary artery.

16. A method of treating a region of cardiac tissue, comprising the steps of:

a) perfusing the region of cardiac tissue, including administering a therapeutic agent to the region, the therapeutic agent being selected to treat microvascular obstructions; and

b) monitoring the region after perfusion of the region for microvascular obstructions, including advancing an assessment tool into a patient'"'"'s coronary artery and obtaining feedback related to a likelihood of microvascular obstructions from the assessment tool.

17. The method of claim 16, wherein the assessment tool includes a flow rate measurement device that is advanced into the patient'"'"'s coronary artery.

18. The method of claim 16, wherein the assessment tool includes a pressure sensor that is advanced into the patient'"'"'s coronary artery.

19. The method of claim 16, further including systemically isolating the administered therapeutic agent by withdrawing the agent prior to systemic circulation.

20. The method of claim 19, wherein the step of systemically isolating includes withdrawing the therapeutic agent and an amount of blood.

21. The method of claim 16, further including treating an occlusion at a cardiac occlusion location prior to perfusing the region, the cardiac occlusion location being proximal to the region.